Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Sage Therapeutics Inc | SAGE | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 14.00 | 04:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 14.00 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 10.92 - 59.99 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 14.00 | USD |
Sage Therapeutics (SAGE) Options Flow Summary
Sage Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 841.49M | 60.11M | - | 86.46M | -541.49M | -9.01 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Sage Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SAGE Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 12.24 | 14.52 | 12.20 | 13.40 | 1,429,844 | 1.76 | 14.38% |
| 1 Month | 19.06 | 19.34 | 10.92 | 14.81 | 1,215,972 | -5.06 | -26.55% |
| 3 Months | 25.75 | 27.39 | 10.92 | 19.46 | 1,049,068 | -11.75 | -45.63% |
| 6 Months | 18.77 | 28.26 | 10.92 | 20.63 | 963,482 | -4.77 | -25.41% |
| 1 Year | 46.82 | 59.99 | 10.92 | 25.69 | 1,093,341 | -32.82 | -70.10% |
| 3 Years | 77.42 | 80.87 | 10.92 | 34.72 | 769,840 | -63.42 | -81.92% |
| 5 Years | 165.72 | 193.56 | 10.92 | 49.78 | 753,635 | -151.72 | -91.55% |
Sage Therapeutics Description
| Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the study of the nervous system and brain to discover medicines to treat life-threatening, rare central nervous system disorders. The company's lead development program is SAGE-217 program which is in Phase 3 clinical trials for post-partum depression, essential tremor, Parkinson's disease, and major depressive disorder. The company is also developing several other compounds for treatment that are in the early stage of development. |
